Strahlentherapie und Onkologie

, Volume 194, Issue 4, pp 356–357 | Cite as

Nivolumab für das vorbehandelte metastasierte Analkarzinom

Blockade von Immuncheckpoints auch in Kombination mit Radiochemotherapie sinnvoll
Literatur kommentiert
  • 82 Downloads

Nivolumab for pretreated metastatic anal cancer

Immune checkpoint blockade is also advised in combination with radiochemotherapy

Notes

Interessenkonflikt

D. Martin, C. Rödel und E. Fokas geben an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144.  https://doi.org/10.1056/NEJMoa1305133 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ferris RL, Blumenschein G, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867.  https://doi.org/10.1056/NEJMoa1602252 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yanik EL, Kaunitz GJ, Cottrell TR et al (2017) Association of HIV status with local immune response to anal squamous cell carcinoma: implications for immunotherapy. Jama Oncol.  https://doi.org/10.1001/jamaoncol.2017.0115 PubMedPubMedCentralGoogle Scholar
  4. 4.
    Balermpas P, Martin D, Wieland U et al (2017) Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: rationale for immunotherapy. Oncoimmunology 6:e1288331.  https://doi.org/10.1080/2162402X.2017.1288331 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hu W‑H, Miyai K, Cajas-Monson LC et al (2015) Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. J Surg Oncol 112:421–426.  https://doi.org/10.1002/jso.23998 CrossRefPubMedGoogle Scholar
  6. 6.
    Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571.  https://doi.org/10.1038/nature13954 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Snyder A, Makarov V, Merghoub T et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199.  https://doi.org/10.1056/NEJMoa1406498 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Martin D, Rödel F, Balermpas P et al (2017) The immune microenvironment and HPV in anal cancer: rationale to complement chemoradiation with immunotherapy. Biochim Biophys Acta 1868:221–230.  https://doi.org/10.1016/j.bbcan.2017.05.001 PubMedGoogle Scholar
  9. 9.
    Badoual C, Hans S, Merillon N et al (2013) PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73:128–138.  https://doi.org/10.1158/0008-5472.CAN-12-2606 CrossRefPubMedGoogle Scholar
  10. 10.
    Liu C, Lu J, Tian H et al (2017) Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. Mol Med Rep 15:1063–1070.  https://doi.org/10.3892/mmr.2017.6102 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Partlová S, Bouček J, Kloudová K et al (2015) Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology.  https://doi.org/10.4161/21624011.2014.965570 PubMedPubMedCentralGoogle Scholar
  12. 12.
    Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16:e498–e509.  https://doi.org/10.1016/S1470-2045(15)00007-8 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Strahlentherapie und OnkologieGoethe Universität FrankfurtFrankfurtDeutschland

Personalised recommendations